Trinity Biotech to submit IND for Uni-Gold HIV test within next three months.
This article was originally published in The Gray Sheet
TRINITY BIOTECH UNI-GOLD HIV TEST INVESTIGATIONAL NEW DRUG SUBMISSION is expected within the next three months, the Dublin, Ireland-based company says. Clinical trials for the product will be conducted under FDA's new drug/biologic investigation procedures, and the company will attempt to bring the one-step HIV assay to market via a product license application (PLA) that will be reviewed by FDA's Center for Biologics Evaluation and Research. FDA is requiring Trinity to submit a PLA rather than a premarket approval application since the assay potentially could be used to screen blood, the firm explains.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.